New eye drop aims to soothe dry, irritated eyes

NCT ID NCT07264517

Completed Symptom relief Sponsor: Instituto Grifols, S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental eye drop called GRF312 5% in 100 adults with dry eye disease. The goal is to see if it is safe and helps relieve symptoms. Participants will use the drops at home and attend clinic visits for check-ups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE

Contacts and locations

Locations

GC2302 Study Site 101

Garner, North Carolina, 27529, United States
GC2302 Study Site 102

Memphis, Tennessee, 38119, United States
GC2302 Study Site 103

Newport Beach, California, 92663, United States
GC2302 Study Site 104

Asheville, North Carolina, 28803, United States
GC2302 Study Site 105

Morrow, Georgia, 30260, United States
GC2302 Study Site 106

Carmel, Indiana, 46290, United States
GC2302 Study Site 107

Cranberry Township, Pennsylvania, 160166, United States
GC2302 Study Site 109

Grove, California, 92843, United States
GC2302 Study Site 110

Glendale, California, 91204, United States
GC2302 Study Site 111

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.